Corbeille-Essonnes (near Paris), France – March 24, 2021 – Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) dedicated to the production of gene therapy drugs, today announces that Brian Mullan, Ph.D, head of development and innovation at Yposkesi will present at the annual Cell & Gene Meeting on the Mediterranean being held virtually April 6-9.

 

Challenges in increasing yields in gene therapy vector production have created a bottleneck for developers of gene therapies seeking to advance clinical trials and commercialize new therapeutic drugs. Novel manufacturing approaches are being developed to improve yields.

 

Dr. Mullan will share insights on developments in impurity management, automation for analytical testing, and plug and play approaches, among others.

 

Event: 2021 Virtual Cell & Gene Meeting on the Mediterranean

 

Title of presentation: Gene Therapy Vectors: Challenges for Supply Commercialization

 

Date: Tuesday, April 6 – Friday, April 9

 

Time: Company presentations will be available to view on- demand throughout the entirety of the conference

 

The Cell & Gene Meeting on the Mediterranean is organized by the Alliance for Regenerative Medicine as a four-day virtual conference. It features more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies. The meeting also includes over 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization.

 

Please visit www.meetingonthemed.com for full information including registration.

 

About Yposkesi

Yposkesi is a leading Contract Development & Manufacturing Organization (CDMO) for gene therapy vector manufacturing. Created in November 2016 in Corbeil-Essonnes (France) by AFM-Telethon and the SPI fund managed by Bpifrance, Yposkesi provides integrated services covering bioprocess development (USP & DSP) from small/pilot to large-scale production, analytical development, GMP manufacturing of lentiviral and AAV vectors and regulatory support. Its current facility consists of a 50,000ft2 (approx. 5,000m2) building, operating multiple manufacturing suites for bulk drug substance and Fill & Finish. By 2022, Yposkesi will increase its global footprint to 100,000ft2 (approx. 10,000m2) with a second large-scale facility

designed for EMA and FDA compliance. Capitalizing on the more than 25 years’ expertise of Genethon, Yposkesi invests significantly in innovation in bioprocessing to deliver on high-quality projects, cost-effectively.
www.yposkesi.com